CLINICAL TRIALS PROFILE FOR VYNDAQEL
✉ Email this page to a colleague
All Clinical Trials for VYNDAQEL
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02146378 ↗ | Vyndaqel Drug Use Investigation (Regulatory Post Marketing Commitment Plan) | Active, not recruiting | Pfizer | 2014-01-10 | The purpose of this study is to understand safety (e.g., occurrence of adverse drug reactions [ADRs]) and efficacy data on the long-term use of Vyndaqel Capsules (hereinafter referred to as Vyndaqel) in all patients who received this drug under actual use conditions after its marketing. | |
| NCT02217813 ↗ | A Bioequivalence Study Comparing Two Different Tafamidis Formulations | Completed | Pfizer | Phase 1 | 2014-10-01 | Each subject will be given tafamidis. After swallowing a single tafamidis capsule, tafamidis blood concentrations will be measured periodically for one week. After about 20 days, subjects will take a different form of tafamidis capsule and the process repeated. Tafamidis concentrations from the two different formulations will be compared to determine if they are approximately the same. |
| NCT04253353 ↗ | A Drug-Drug Interaction Study To Estimate The Effect Of Tafamidis On Rosuvastatin Pharmacokinetics | Completed | Pfizer | Phase 1 | 2020-02-06 | Each subject will be given a single oral dose of rosuvastatin on Day 1 in Period 1. In Period 2, after a washout period of at least 5 days, each subject will receive oral doses of tafamidis twice daily (BID) on days 1 and 2, followed by tafamidis once daily (QD) on days 3 to 9 with an oral dose of rosuvastatin on Day 7. Rosuvastatin exposures will be compared between Periods 1 and 2 to estimate the effect of tafamidis on rosuvastatin PK in healthy subjects. |
| NCT04828993 ↗ | The Effect Of Tafamidis Meglumine In Transthyretin Amyloid Polyneuropathy Patients | Recruiting | Pfizer | Phase 4 | 2021-04-28 | This is a single-arm, open-label, multicenter study designed to determine the effect of tafamidis meglumine on TTR stabilization as well as tafamidis meglumine safety, tolerability and efficacy in ATTR-PN patients in China. Approximately 10-15 participants are planned to be enrolled. All enrolled participants will receive oral tafamidis meglumine 20 mg soft capsules once daily for 48 weeks. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for VYNDAQEL
Condition Name
Clinical Trial Locations for VYNDAQEL
Clinical Trial Progress for VYNDAQEL
Clinical Trial Phase
Clinical Trial Sponsors for VYNDAQEL
Sponsor Name
